Fortacin™
Premature Ejaculation (PE)
ApprovedActive
Key Facts
About Plethora Solutions
Plethora Solutions is a London-based, publicly listed specialty pharma company concentrating on the urology therapeutic area. The company's lead product is Fortacin™, a treatment for premature ejaculation (PE) that has achieved European Commission marketing authorization, positioning it in the commercial stage. With over 25 million men in Europe affected by PE, Plethora is targeting a substantial market with high unmet need. The company's strategy involves the development and marketing of pharmaceutical products and medical devices for urological conditions.
View full company profile